Point Therapeutics Presents Preclinical Anti-Tumor Data of Talabostat in Combination with Pemetrexed and Erlotinib at AACR-EORTC
November 17 2005 - 8:30AM
Business Wire
Point Therapeutics, Inc. (NASDAQ:POTP) presented preclinical data
on its lead product candidate talabostat, demonstrating anti-tumor
activity when combined with either pemetrexed or erlotinib in a
non-small lung cancer (NSCLC) xenograft model in immunodeficient
mice at a poster session today at the AACR-EORTC-NCI International
Conference on Molecular Targets and Cancer Therapeutics in
Philadelphia, PA. As a single agent, talabostat caused a 35%
greater reduction in tumor size than pemetrexed alone.
Administration of 500 mg/kg of pemetrexed alone did not
significantly impact tumor growth. When talabostat and pemetrexed
were combined, the anti-tumor effect was significantly greater (p
Point Therapeutics (MM) (NASDAQ:POTP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Point Therapeutics (MM) (NASDAQ:POTP)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Point Therapeutics (MM) (NASDAQ): 0 recent articles
More Point Therapeutics, Inc. News Articles